Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report

HIGHLIGHTS

• who: Dipeptidyl peptidase IV inhibitor and collaborators from the Ten volunteers, including eight men and two women, were recruitedThe study consisted of two, week cross-over treatment periods with , mg/day alogliptin and placebo in random order, including a, week washout period between the two phases. All participants underwent medical checkups. None of the , volunteers had hypertension, impaired glucose tolerance, dyslipidemia, or cerebrovascular or cardiovascular disease, but three volunteers were current smokers. Family histories were obtained from medical interviews. Impaired glucose tolerance was defined as, h glucose level of, mg/dl after the meal loading test [13 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.